Takeda Pharmaceutical (TAK) Non-Current Debt (2018 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Non-Current Debt of $3.7 billion for Q2 2026, up 1.19% year-over-year from $3.7 billion in Q2 2025, and up 2.74% quarter-over-quarter from $3.6 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Non-Current Debt (2018 - 2026) Analysis & Trends
Takeda Pharmaceutical's Non-Current Debt history runs 9 years deep, the most recent figure standing at $3.7 billion for Q2 2026.
- In Q2 2026, Non-Current Debt rose 1.19% year-over-year to $3.7 billion; the TTM figure through Jun 2026 stood at $3.7 billion (up 1.19% YoY), while the FY2026 annual figure was $3.8 billion, down 85.43% from the prior year.
- Non-Current Debt for Q2 2026 stood at $3.7 billion, up from $3.6 billion in the prior quarter.
- The five-year high for Non-Current Debt was $35.6 billion in Q1 2022, with the low at $3.6 billion in Q4 2022.
- The 5-year median for Non-Current Debt is $3.8 billion (2024), against an average of $6.8 billion.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt soared 628.65% in 2022, then slumped 88.67% in 2023.
- Takeda Pharmaceutical's Non-Current Debt stood at $3.6 billion in 2022, then advanced by 2.9% to $3.7 billion in 2023, then climbed by 6.03% to $3.9 billion in 2024, then declined by 4.98% to $3.7 billion in 2025, then advanced by 1.29% to $3.7 billion in 2026.
- Business Quant data shows TAK's Non-Current Debt at $3.7 billion in Q2 2026, $3.6 billion in Q1 2026, and $3.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 130.00 Mn |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | 1.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.74 Bn |
| Mar 31, 2026 | 3.64 Bn |
| Dec 31, 2025 | 3.69 Bn |
| Sep 30, 2025 | 3.70 Bn |
| Jun 30, 2025 | 3.70 Bn |
| Mar 31, 2025 | 26.00 Bn |
| Dec 31, 2024 | 3.89 Bn |
| Sep 30, 2024 | 3.74 Bn |
| Jun 30, 2024 | 3.96 Bn |
| Mar 31, 2024 | 4.64 Bn |
| Dec 31, 2023 | 3.67 Bn |
| Sep 30, 2023 | 3.98 Bn |
| Jun 30, 2023 | 3.62 Bn |
| Mar 31, 2023 | 4.04 Bn |
| Dec 31, 2022 | 3.56 Bn |
| Sep 30, 2022 | 3.97 Bn |
| Jun 30, 2022 | 3.93 Bn |
| Mar 31, 2022 | 35.64 Bn |
| Dec 31, 2021 | 4.06 Bn |
| Sep 30, 2021 | 4.22 Bn |